Do PARP inhibitors increase MDS or AML risk? Drs. Iyengar and Robson review long-term OlympiA data and discuss myeloid safety, secondary cancer prevention, and surgical decision-making in BRCA carriers.
Long-Term Safety of PARP Inhibitors: Myeloid Risk and Preventive Considerations
You may also like
Recommended Videos
